GRAIL (GRAL) Expected to Announce Earnings on Tuesday

Key Points

• GRAIL is set to release its Q2 2025 earnings results on August 12, with analysts forecasting a loss of ($3.14) per share and revenue of $37.57 million.
• In its last earnings report, GRAIL beat estimates by reporting ($3.10) EPS, despite a negative net margin of 1,464.53% and revenue lower than expected at $31.84 million.
• Insider trading activity has seen significant sales, with the CFO selling 8,000 shares for approximately $311,440, indicating a 2.72% decrease in ownership.

GRAIL (NASDAQ:GRAL - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 12th. Analysts expect GRAIL to post earnings of ($3.14) per share and revenue of $37.57 million for the quarter.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.03) by $0.93. GRAIL had a negative net margin of 1,464.53% and a negative return on equity of 17.99%. The company had revenue of $31.84 million for the quarter, compared to analysts' expectations of $35.80 million. On average, analysts expect GRAIL to post $-15 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

GRAIL Trading Down 1.6%

GRAL traded down $0.55 on Thursday, reaching $32.54. The stock had a trading volume of 239,833 shares, compared to its average volume of 1,383,095. The firm has a 50-day moving average of $41.12 and a 200-day moving average of $35.81. GRAIL has a fifty-two week low of $12.33 and a fifty-two week high of $63.99. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -0.53 and a beta of 3.26.

Insiders Place Their Bets

In other news, CFO Aaron Freidin sold 8,000 shares of GRAIL stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $38.93, for a total transaction of $311,440.00. Following the transaction, the chief financial officer directly owned 286,020 shares of the company's stock, valued at $11,134,758.60. The trade was a 2.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Chun R. Ding sold 339,800 shares of the firm's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $49.53, for a total transaction of $16,830,294.00. Following the completion of the transaction, the insider directly owned 3,305,055 shares of the company's stock, valued at approximately $163,699,374.15. This trade represents a 9.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 357,492 shares of company stock valued at $17,645,718 in the last 90 days. 1.85% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC raised its stake in shares of GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock valued at $45,000 after purchasing an additional 1,401 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in GRAIL by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company's stock worth $76,000 after purchasing an additional 623 shares during the period. Royal Bank of Canada grew its holdings in shares of GRAIL by 17.7% in the first quarter. Royal Bank of Canada now owns 88,082 shares of the company's stock valued at $2,250,000 after acquiring an additional 13,264 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of GRAIL by 37.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company's stock valued at $2,362,000 after acquiring an additional 25,177 shares during the period.

Analyst Ratings Changes

Separately, Canaccord Genuity Group raised their price target on GRAIL from $32.00 to $43.00 and gave the company a "buy" rating in a report on Wednesday, May 14th.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.